

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN THE COMPOSITION OF THE BOARD COMMITTEES

RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of LifeTech Scientific Corporation (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that the Board received a letter of resignation from Mr. WANG Wansong (“**Mr. WANG**”) whereby he tendered his resignation as an independent non-executive Director and his positions as chairman of the remuneration committee of the Company (the “**Remuneration Committee**”) and a member of each of the audit committee (the “**Audit Committee**”) and nomination committee (the “**Nomination Committee**”) of the Company with effect from 26 January 2026 in order to meet the requirements of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to long-serving independent non-executive Directors who have served for more than nine years.

Mr. WANG confirmed that he has no disagreement in any aspect with the Company or the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange. The Board would like to express its sincere appreciation to Mr. WANG for his valuable contribution to the Company during the tenure of his service as an independent non-executive Director.

Following the resignation of Mr. WANG, the Company only has two independent non-executive Directors, the number of independent non-executive Directors and number of members of each of the Audit Committee, Nomination Committee and Remuneration Committee falls below the number required under Rules 3.10(1), 3.21

and 3.25 of the Rules Governing the Listing of Securities of the Stock Exchange (the “**Listing Rules**”). The Board will make its best endeavours to identify suitable candidate to fill the vacancy as soon as practicable and in any event within three months from the date of resignation of Mr. WANG in order to ensure compliance by the Company with the requirements under the Listing Rules. The Company will further make an announcement as soon as practicable after the appointment of the new independent non-executive Director.

CHANGES IN THE COMPOSITION OF THE BOARD COMMITTEES

The Board hereby announces that with effect from 26 January 2026:

- (i) Mr. WANG ceased to be the chairman of the Remuneration Committee and a member of each of the Audit Committee and Nomination Committee; and
- (ii) Ms. CHEN Dongxia has been appointed as the chairlady of the Remuneration Committee.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Executive Director, Chairman
and Chief Executive Officer*

Hong Kong, 26 January 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong, Ms. WU Liping, Mr. FANG Yu and Ms. FENG Xiaoling being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. ZHOU Luming and Ms. CHEN Dongxia being independent non-executive Directors.